Growth hormone treatment in Noonan syndrome: report of four cases who reached final height.
Final height of 4 patients with Noonan syndrome and short stature treated with growth hormone (GH) is reported. Four prepubertal girls (chronological age 12.3-15.1 years, bone age 11.0-11.5 years) were treated with recombinant human growth hormone (0.5 IU/kg/week s.c.) for at least 3 years. Stimulated GH secretion was normal, spontaneous nocturnal GH secretion was low in 1 patient. Final height, as standard deviation score according to Ranke-specific standards for Noonan syndrome, improved in 3 patients and 2 of the exceeded their corrected midparental height.
Municchi
G
G
Pediatric Department, University La Sapienza, Rome, Italy.
Pasquino
A M
AM
Pucarelli
I
I
Cianfarani
S
S
Passeri
F
F
D000293:Adolescent; D000365:Age Determination by Skeleton; D001827:Body Height / Q000187:drug effects*; D002648:Child; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D009634:Noonan Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D013006:Growth Hormone